|
|||||
|
|
A randomized,placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease |
|
| Authors: | Ralf Reilmann MD Marie-Laure Rouzade-Dominguez PhD Carsten Saft MD Sigurd D. Süssmuth MD Josef Priller MD Anne Rosser PhD Hugh Rickards MD Ludger Schöls MD Nicole Pezous MA Fabrizio Gasparini PhD Donald Johns MD Georg Bernhard Landwehrmeyer MD Baltazar Gomez-Mancilla MD |
| Affiliation: | 1. George-Huntington-Institute, Münster, Germany Institute for Clinical Radiology, University of Münster, Münster, Germany Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany;2. Clinical Sciences and Innovation, Novartis Pharma AG, Basel, Switzerland;3. Department of Neurology, Huntington Center NRW, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany;4. Department of Neurology, Ulm University, Ulm, Germany;5. Department of Neuropsychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany;6. Cardiff University Schools of Medicine and Biosciences, Neuroscience and Mental Health Research Institute, Cardiff, United Kingdom;7. Department of Neuropsychiatry, The Barberry, Birmingham, United Kingdom;8. Clinical Neurogenetics Unit, Center of Neurology and Hertie-Institute for Clinical Brain Research, Tübingen, Germany German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany;9. IIS Translational Sciences–Early Development Statistical Research, Novartis Pharma AG, Basel, Switzerland;10. Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland;11. Neuroscience Translational Medicine, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts, USA;12. Department of Neurology, Ulm University, Ulm, Germany These authors contributed equally to this work. |
| Abstract: | |
| Keywords: | Huntington's disease chorea mGluR5 antagonist AFQ056 |